Clinical trial · Observational
Efficacy and Safety of Ultrapulse Carbon Dioxide Laser Treatment in Eyelid Tumors
NCT06206681CI-TRIAL-00074815unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to assess the long-term efficacy and safety of ultrapulse carbon dioxide (CO₂) laser excision in the treatment of eyelid tumors, including xanthelasma, pigmented nevi, keratoses, and so on.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Eyelid Tumor | Eyelid Neoplasm | ALIAS | 0.90 |
| Keratosis | — | UNRESOLVED | — |
| Pigmented Nevi | — | UNRESOLVED | — |
| Xanthelasma Palpebrarum | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ultra-pulsed Carbon Dioxide Laser | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Ultrapulse Carbon Dioxide Laser
- description
- The study investigates the use of the Ultrapulse Carbon Dioxide Laser for the excision of eyelid lesions, including xanthelasma, pigmented nevi, keratoses, and so on.
- interventionNames
- Procedure: Ultra-pulsed Carbon Dioxide Laser
Primary outcomes (2)
- measure
- Clearance rate
- timeFrame
- 12 months
- description
- The lesion clearance rate was classified as the proportion of the lesion cleared (\<50%; 50-75%; 76-99%; or \>99%).
- measure
- Recurrence rate
- timeFrame
- 12 months
- description
- Recurrence was defined as the regrowth of a new xanthelasma lesion within the previously excised area.
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Clinically diagnosed with eyelid lesions, including xanthelasma, pigmented nevi, keratoses, and so on. * No history of photosensitivity, bleeding, or coagulation disorders * Willing to attend follow-up appointments as scheduled Exclusion Criteria: * Presence of infection in the target area * Allergy to lidocaine * Keloid-prone or poor skin repair ability * Pregnant or lactating * Recent history of severe infectious diseases, active skin diseases, or major diseases affecting the cardiovascular, liver, kidney, endocrine, and hematopoietic systems * History of malignant tumors or immune system disorders
References
Publications (0)
Data not yet available
No reference posted for this study.